Please assess the completion status of the following clinical trial:

Trial Title: Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must be able to provide written informed consent.~2. Subjects must be healthy as established by medical history and clinical examination at study entry~3. Subjects who the investigator believes can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits, etc.)~4. Subjects at WRAIR CTC must be able to pass Department of Defense (DoD) base entry requirements, including the possession of a valid government issued ID card.~5. Male or non-pregnant, non-breastfeeding female between 20 and 49 years of age (inclusive) at the time of consent~6. Female subjects of non-childbearing potential (non-childbearing potential is defined as having had one of the following: a tubal ligation at least 3 months prior to enrollment, a hysterectomy, an ovariectomy, or is post-menopausal).~7. Female subjects of childbearing potential may be enrolled in the study, if all of the following apply:~   * Practiced adequate contraception (see Definition of Terms, section 5) for 30 days prior to vaccination~  * Has a negative urine pregnancy test on the day of vaccination~  * Agrees to continue adequate contraception until two months after completion of the vaccination series.~Exclusion Criteria:~1. Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines/placebo during the period starting 30 days preceding the first dose of study vaccine/placebo and/or planned use during the study period~2. Chronic administration (defined as more than 14 days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first vaccine/placebo dose (for corticosteroids, this will mean prednisone \>=5mg/day or equivalent; inhaled, intranasal and topical steroids are allowed)~3. Planned administration or administration of a vaccine/product not planned in the study protocol during the period starting 30 days prior to the first dose of vaccine/placebo until 30 days after the last dose of study vaccine/placebo (routine influenza vaccination will be allowed as long as it is not administered within 14 days of the vaccine/placebo, and will not lead to study exclusion although it should be reported to the PI)~4. History of dengue infection or dengue illness, or history of flavivirus vaccination (e.g., yellow fever, tick-borne-encephalitis virus \[TBEV\], Japanese encephalitis, and dengue)~5. Planned administration of any flavivirus vaccine for the entire study duration~6. Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device)~7. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required)~8. Family history of congenital or hereditary immunodeficiency~9. Autoimmune disease or history of autoimmune disease~10. History of any reaction or hypersensitivity likely to be exacerbated by any component of the study vaccine/placebo or related to a study procedure~11. Major congenital defects or serious chronic illness~12. History of any neurological disorders or seizures~13. Diagnosed with excessive daytime sleepiness (unintended sleep episodes during the day present almost daily for at least 1 month) or narcolepsy; or history of narcolepsy in a subject's parent, sibling, or child~14. Acute disease and/or fever (≥37.5°C/99.5°F oral body temperature) at the time of enrollment: note that a subject with a minor illness such as mild diarrhea, mild upper respiratory infection, etc., without fever, may be enrolled at the discretion of the investigator~15. Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests~16. Administration of immunoglobulins and/or any blood products during the period starting 90 days preceding the first dose of study vaccine/placebo or planned administration during the study period~17. Recent history of chronic alcohol consumption (more than 2 drinks per day and/or drug abuse (based on subject reported history)~18. Pregnant or breastfeeding female or female currently planning to become pregnant or planning to discontinue adequate contraception~19. A planned move to a location that will prohibit participating in the trial until Study End for the participant~20. Any other condition which, in the opinion of the investigator, prevents the subject from participating in the study.~21. Subject seropositive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), or human immunodeficiency virus antibodies (anti-HIV)~22. Safety laboratory test results at screening that are deemed clinically significant or more than Grade 1 deviation from normal

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- TDENV-PIV (0-1) (Type: EXPERIMENTAL): The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 0 and Day 28. The placebo will be administered on Day 84 and Day 168.
- TDENV-PIV (0-1-6) (Type: EXPERIMENTAL): The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 0, Day 28, and Day 168. The placebo will be administered on Day 84.
- TDENV-PIV (0-3) (Type: EXPERIMENTAL): The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.~The placebo is sodium chloride.~TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.~The intervention will be administered on Day 84 and Day 168. The placebo will be administered on Day 0 and Day 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete